ANG Lifesciences India Ltd (ANG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by ANG Lifesciences India Ltd on NSE and BSE, with an AI summary of each filing.
Scrutinizer''s Report for AGM along with Voting Results
Annual General Meeting · 01 Oct 2026, 6:44 pm
Re-appointment of Ms. Chetna as the Independent Director of the company.
Change in Management · 30 Sept 2026, 11:16 pm
ANG Lifesciences Approves Reappointment of Independent Director Mrs. Chetna ANG Lifesciences India Limited has received shareholder approval at its 20th Annual General Meeting for the reappointment of Mrs. Chetna (DIN: 08981045) as an Independent Director. Her second consecutive five-year term is effective from 12th Oct'26 through 11th Oct'31. Mrs. Chetna holds qualifications in Law, Company Secretarial practice, and an MBA in Finance, possessing expertise in corporate law, SEBI compliances, and taxation. She is not related to any directors or Key Managerial Personnel and is not debarred by SEBI.
Proceedings of 20th Annual General Meeting are enclosed herewith.
Annual General Meeting · 30 Sept 2026, 11:10 pm
Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('''' Listing Regulations''''), please find attached herewith the Annual Report of the Company for the ....
Others (Uncategorized) · 08 Sept 2026, 4:26 am
Notice of 20th AGM
Annual General Meeting · 08 Sept 2026, 2:19 am
Intimation of 20th Annual General Meeting
Annual General Meeting · 08 Sept 2026, 2:03 am
This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....
Others (Uncategorized) · 08 Sept 2026, 1:56 am
Financial Results 30.06.2026.
Financial Result · 15 Aug 2026, 12:00 am
ANG Lifesciences Reports Wider Loss for Q1 FY27 on Revenue Decline For Q1 ending 30 Jun'26, ANG Lifesciences posted a consolidated net loss of ₹424.42 lakhs, widening from a ₹200.62 lakh loss YoY. This was driven by a 38.1% YoY fall in revenue from operations to ₹1,529.77 lakhs. QoQ, revenue declined 34.9% and the net loss increased from ₹138.18 lakhs. The core Pharmaceuticals segment saw revenue drop 39.0% YoY to ₹1,395.79 lakhs. The company reported a negative EPS of (₹3.24), down from (₹1.52) YoY and (₹1.07) QoQ, indicating significant operational headwinds.
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015
Outcome · 14 Aug 2026, 11:55 pm
ANG Lifesciences India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 1,530 (-37.8% YoY | -34.9% QoQ) ■ EBITDA: -195 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -12.8 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -424 (-111.6% YoY | -207.2% QoQ) ■ EPS (INR): -3.24 (-113.2% YoY | -202.8% QoQ) ANG Lifesciences India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceuticals ■ Revenue: 1,396 (-43.1% YoY | -38.8% QoQ) ■ EBIT: -274 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -19.6 (Profit to Loss YoY | Profit to Loss QoQ) Printing and packagings ■ Revenue: 212 (+517.0% YoY | +22.8% QoQ) ■ EBIT: -47.7 (+62.0% YoY | +74.6% QoQ) ■ EBIT Margin (%): -22.5 (+34295 bps YoY | +8642 bps QoQ)
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....
Intimation · 14 Aug 2026, 5:30 am
ANG Lifesciences Board to Approve Q1FY27 Results on 14th Aug'26 ANG Lifesciences India's Board of Directors will meet on 14th Aug'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended 30th Jun'26. In accordance with SEBI regulations, the trading window for insiders has been closed from 01st Jul'26 and will reopen 48 hours after the financial results are publicly disclosed on 14th Aug'26.
Audited Results 31.03.2026
Financial Result · 31 May 2026, 3:50 am
ANG Lifesciences Reports Q4 FY26 Results, Narrows Losses YoY ANG Lifesciences reported consolidated results for the quarter ended 31 Mar'26, with revenue from operations at ₹2,350.22 lakhs, up 39.7% YoY. Net loss narrowed significantly to ₹138.18 lakhs from a loss of ₹206.05 lakhs in the prior year's quarter. For the full year FY26, revenue stood at ₹9,289.28 lakhs, while net loss was ₹1,108.48 lakhs, an improvement from FY25's loss of ₹1,241.33 lakhs. The auditors issued an unmodified opinion with an Emphasis of Matter noting defaults on loan repayments and delays in statutory due payments.
Audited Financial Results for the quarter and year ended 31st March, 2026
Outcome · 31 May 2026, 3:45 am
ANG Lifesciences India Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 2,350 (+39.7% YoY | +25.5% QoQ) ■ EBITDA: 267 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 11.4 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: -138 (+32.9% YoY | +70.9% QoQ) ■ EPS (INR): -1.07 (+31.4% YoY | +70.3% QoQ) ANG Lifesciences India Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceuticals ■ Revenue: 2,280 (+29.1% YoY | +24.6% QoQ) ■ EBIT: 308 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 13.5 (Loss to Profit YoY | Loss to Profit QoQ) Printing and packagings ■ Revenue: 173 (+378.7% YoY | +3.8% QoQ) ■ EBIT: -188 (-324.6% YoY | -247.0% QoQ) ■ EBIT Margin (%): -109 (+1386 bps YoY | -7634 bps QoQ)
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
Intimation · 30 May 2026, 5:30 am
ANG Lifesciences Board Meeting for Q4 & FY26 Results on May 30 ANG Lifesciences' Board of Directors will meet on 30th May'26 to consider and approve standalone and consolidated audited financial results for the quarter and year ended 31st Mar'26. In accordance with SEBI regulations, the trading window for insiders has been closed from 01st Apr'26. The window will reopen 48 hours after the financial results are publicly announced on 30th May'26.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 17 Apr 2026, 5:06 pm
ANG Lifesciences Confirms Non-Applicability of Large Corporate Framework for FY26 ANG Lifesciences India Ltd informed the exchange on 17-Apr-26 that it does not qualify as a Large Corporate (LC) for the financial year 2025-26. Consequently, the company is not required to meet the mandatory fund-raising obligations through debt securities as stipulated by the SEBI circular. The filing confirms the company's outstanding borrowing was ₹0.00 Cr as of the last applicable reporting date. ANG Lifesciences will notify the exchange if it meets the LC criteria in the future.
This is with reference to the email communication received from BSE Limited on April 09,2026 seeking clarification for a significant movement in the price of the securities of the company.
Others (Uncategorized) · 10 Apr 2026, 8:39 pm
ANG Lifesciences Clarifies Recent Stock Price Movement to BSE ANG Lifesciences, in a 10-Apr-2026 response to a BSE query, stated it has no additional price-sensitive information to disclose that could explain its recent share price movement. The company confirmed it is in compliance with SEBI's Regulation 30 disclosure requirements. Management asserted that the stock's price behavior is purely market-driven, and the company has no control over or knowledge of the specific reasons behind it. They have disseminated all required price-sensitive information to the exchange as mandated.
The Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 10 Apr 2026, 1:46 pm
Unaudited Financial Results 31.12.2025.
Financial Result · 15 Feb 2026, 1:23 am
ANG Lifesciences Reports Wider QoQ Loss Amid Revenue Decline in Q3 FY26 ANG Lifesciences posted a consolidated net loss of ₹474.96 lakhs for Q3 FY26, widening from a ₹294.74 lakh loss QoQ, though narrowing from a ₹519.07 lakh loss YoY. Revenue from operations for the quarter ended 31 Dec'25 fell 28.1% QoQ and 24.2% YoY to ₹1,873.33 lakhs. The loss was driven by higher expenses relative to sales. For the nine months ended 31 Dec'25, the company's net loss stood at ₹970.32 lakhs with a negative EPS of ₹(7.36).
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
Outcome · 15 Feb 2026, 1:21 am
ANG LIFESCIENCES INDIA LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 1873 (-24.2% YoY | -28.1% QoQ) ■ EBITDA: -269 (-25.2% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -14.4 (-567 bps YoY | Profit to Loss QoQ) ■ PAT: -475 (+8.5% YoY | -61.1% QoQ) ■ EPS (INR): -3.60 (+9.5% YoY | -60.7% QoQ) ANG LIFESCIENCES INDIA LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) Segmental Performance Pharmaceuticals ■ Revenue: 1830 (-23.4% YoY | -29.5% QoQ) ■ EBIT: -337 (+12.5% YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -18.4 (-231 bps YoY | Profit to Loss QoQ) Printing and packagings ■ Revenue: 166 (+22.6% YoY | +47.1% QoQ) ■ EBIT: -54.2 (-30.7% YoY | +75.1% QoQ) ■ EBIT Margin (%): -32.6 (-203 bps YoY | +15964 bps QoQ)
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Intimation · 14 Feb 2026, 5:30 am
ANG Lifesciences Board Meeting to Approve Q3FY26 Results ANG Lifesciences (BSE: 540694) scheduled a Board of Directors meeting on 14th Feb'26 to consider and approve its standalone and consolidated unaudited financial results for the quarter and nine months ending 31st Dec'25. The company announced a trading window closure for insiders, effective from 01st Jan'26 until 48 hours after the financial results are made public on 14th Feb'26. This action is in compliance with SEBI insider trading regulations.
Unaudited Financial Results for the Quarter and Half year ended 30.09.2025.
Financial Result · 15 Nov 2025, 12:08 am
Considered and approved the financial results for the quarter and half year ended 30th September 2025
Outcome · 15 Nov 2025, 12:04 am
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to the Regulation ....
Intimation · 14 Nov 2025, 5:30 am
Scrutinizer''s Report along with voting Results
Annual General Meeting · 01 Oct 2025, 10:38 pm
Appointment of Secretarial Auditor
Change in Auditor · 30 Sept 2025, 7:22 pm
Proceedings of the 19th AGM of the company are enclosed herewith.
Annual General Meeting · 30 Sept 2025, 7:19 pm